# Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

> **Open Intelligence Dossier** · First detected: 2026-06-14 14:07 UTC · Category: Business

## Executive Summary
Eli Lilly reports positive initial Phase 1 clinical data for its $2.3 billion acquisition of Ajax Therapeutics' myelofibrosis treatment.

## Intelligence Brief
Eli Lilly has released the first clinical findings regarding AJX-101, a type II JAK2 inhibitor developed by Ajax Therapeutics. Data from the Phase 1 study indicates that the drug, also referred to as AJ1-11095, reduced spleen size and alleviated symptoms in patients with previously treated myelofibrosis.


Coverage from outlets including BioSpace, Yahoo Finance, and Fierce Biotech highlights the drug's efficacy as a potential expansion of Lilly’s pipeline beyond obesity treatments. These reports emphasize that the findings are being presented at the 2026 EHA Annual Meeting, noting the clinical performance of the treatment among patients who had previously used type I JAK inhibitors.


Future developments hinge on subsequent clinical trial phases. Coverage does not yet specify a timeline for further testing or potential regulatory submissions for the therapy.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioSpace | Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxNLWNvNTdWdUxObV92VVNjTVhJc0FTUW1OZmZXWGdaRjd6eE1jU2xVckszcjBHZEN3NnJ0bVI4LVZOYm52RzRFa0ZZVTBKUmtrajBXNWlzLWltaDNXckk1cmdmNi1veS1qVENtN0FERU1wMmpmLTY0TlMwaE1zS1F5MnEybmFsbkhaNUFmY2hJVnJuVnVsVHBrZnR3ZEFFQjB5VW53MVBYN3lIamNTRm5LRGh5eHlHZHdkdnJkNlBiNUpSQQ?oc=5) |
| Yahoo Finance | Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxOVDlxR3p5UlB0SVZCQlFiTURRREo1SFBJdUR2MFdfV1EyekNDM3hRUEN3allqM0VtTGNEaTFYcVI1blV0LUF2TVZMd2RTcTJyQi1qbWgzU0dReERyZzJtWU9hTU1mbUVoOEliWnJWelZQdGZXeFNMN3VtdW5ZN2tZQzJ0ZE9FR2JQaVktVjlMb0VFNDFKZDVvZ1B0WjUtQmdB?oc=5) |
| TipRanks | Eli Lilly announces new data from Phase 1 AJX-101 study | [Source Link](https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRjdoYk5wNGFDcEwwUXNEWmdXd0pjLWVubHZxVW1ZaHRrNlZNbm1tUGk0WVhxcjlmQ2VNSFVyVkt2bl8zcjNYSFZGTGF6VjlneEgyTk1PcDI4SGJmZFRWcmR2Yk1wZXZFdERPclpwTldaSGlscThmV2lZSmFlMl9QTkdzS1pKNGNLWk9qcHBfMjhabl9VODlkXzFZekVmYk5Dd0ZKd25TOHg?oc=5) |
| GuruFocus | Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxQN0tkbjNiMTNESlJ4TGY4Ny1nQV9qdjVzOEdiOGpWNS03TVZEOVB2YTZLTWFWQm5qMk1MUlRsMlFOV3podXN5V2Z3ME51bkhfbDZtdVFSbHQxN0lDSHVzY0tOY2VsUThRZkpRTG55Vi0tYW9kOTdmQ1lOcTlWTThYZjVmUnVkNnlzQ19hRWFyeHdXSWF2Vk1qSkRsY1Yzb1lVVmNKbUZGYU93cmhOVjNFdFJxLTFvZ0lfX3RlUWVROWYxQQ?oc=5) |
| Stock Titan | Lilly trial drug cuts spleen size, symptoms in myelofibrosis | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbExhUEhNY0JkVFdfSV9mUnJ5UG9vT21WNWJxanQxa0llWFljVTZjRXptUkkzOER0dG1rNW1aS3hZeUtQYUxyT3hkUlhpUXlKM2ZCdEdUdDdvdU9hX29nM0l1TXFleWVnbWhQaC01cjEwSjRqbVZ1b0xleEpYTXVpSHlIOFdCWF9aSW5qbTNCekNmb3ljOEF0NnA3VGhqeDZrckh3eXA0QlZBTkRlS0U0clNMUHZSLVVLVy1z?oc=5) |
| OncLive | AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis | [Source Link](https://news.google.com/rss/articles/CBMixwFBVV95cUxNbFR1aWpHUVU4ZTFOUUIxdHNtZ0VjOU1md20wQW1nQXowVkMxdTVSYjFzRURveEx5RFFWaEY0SGZqRXBIbjBmMjE2b016WHBvTGNPSkdRQ1lZOE9taENyejE4TWNnTTdJV251cHNtb1JHWmhiUUZ5NkpBSU03SVhIdk9yTXMxS1RPWkxIenFmbDV0ZEhSWjFLZzhzQjZ3UHVmT01FajViRF9xaHhBZlNidkd0dmhmQnpSUkxUeFZUZTlqRUxjYU5j?oc=5) |
| investor.lilly.com | Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxQcS14VUFEd1lNLUk2Y0tTUzIxdXVyZElCdDhOSGVQeGNlYmdFVXF1aXRDekJXNTFaZzVfbjBWTnFmU0ltWlVpSk44Zk9Va2VKTlZEYUR4LWo0X3doZXhBQ2NoLVBxUGoxVlRBX01hcTRFRnNvVldwYk9BSEpJUktJcy1HOWc0RFBVU0hSejhPQWFBV2NXQjVxSWx4VXBmNXpfcjQtWXZueW91WHNnd2gyRWU5X3BwRXpfSk45SFZBVQ?oc=5) |
| Fierce Biotech | Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxPYUtsSUZPTlFvVTlMNXJ3S3BBT1oyQ25La3ZMQmNhZV9kc3FydGZ4c2t4VW9iOWlJUklrd2dMQjNvWGxGWnM0TFFBX2tZYXh1dkJsQWZQT2kxLVFjVk1GYWUwbHpXWDZlcjFNcnVweDc2X2ZZbGRtaloycF9JOXZzX3ZveXI0cVpUQV9WcUpUT0xsYlBiR3dxTEdLMmk3Vm9yMTl4akNpTW0yY0x4SHNGQmRB?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-06-14/lilly-unveils-first-clinical-data-behind-2-3b-ajax-deal-showing-jak-inhibitor*